BCDA.US Biocardia Inc

Healthcare Biotechnology USA Stocks
0.8310 USD
Close of Nov 14, 2026
0.6600 1.50
Market cap
USD 12.6M
P/E
-
P/B
15.07x
ROE
-908.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is BCDA.US undervalued?

Graham number

The Graham number of Biocardia Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biocardia Inc fundamental analysis

No fundamental analysis for Biocardia Inc yet.

Biocardia Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biocardia Inc

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an alloge…

Full company profile